Filing Flows › Health Care › Vera Therapeutics (VERA)
Vera Therapeutics (VERA) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Nov 5, 2026 · Vera Therapeutics (VERA) Q3 2026 earnings results →
Q3 2026 912¢ of every $1 of revenue lost · operating margin -931.2%
Vera Therapeutics made $10.3M in Q3 2026. Operating margin -931.2%, net loss $93.7M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 5, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $10.3M in Q3 2026.
Operating costs exceeded revenue by $95.7M, an operating margin of -931.2%. The quarter ended with a net loss of $93.7M.
Operating cash flow was −$99.2M. Non-cash charges added back $823K of depreciation and amortization and $15.7M of share-based compensation. Working capital and other items used $22.0M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Nov 5, 2026 | $10.3M | — | -931.2% | −$93.7M | −$99.2M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Vera Therapeutics
Vera Therapeutics is a commercial-stage biotechnology company focused on the pursuit of truth in science to transform medicine in autoimmune disease, starting with the kidney. Vera Therapeutics’ flagship commercial product is TRUTAKNA (atacicept-vymj), a BAFF and APRIL inhibitor indicated to reduce proteinuria in adults with primary IgA nephropathy at risk for disease progression. Beyond IgAN, Vera Therapeutics is evaluating additional diseases where the reduction of autoantibodies through inhibition of BAFF and APRIL may prove clinically meaningful. Vera Therapeutics was founded in 2016 and is based in Brisbane, California. To learn more, visit www.veratx.com .
In its own words, from its 8-K, filed Aug 10, 2026.
Vera Therapeutics against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Operating margin: -931.2% against the peers' median 20.4%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| VERA Vera Therapeutics | Q3 2026 | $10.3M | — | -931.2% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Vera Therapeutics 10-Q on SEC EDGAR · CIK 1831828 · Pharmaceutical Preparations
Guidance and outlook
13F: who owns VERA and who is buying
More on VERA
- How Vera Therapeutics makes money: revenue by segment
- Vera Therapeutics next earnings date and what analysts expect
- Vera Therapeutics stock forecast, price target and fair value
- Who owns Vera Therapeutics stock: holders, funds and Congress trades
- Vera Therapeutics guidance and outlook
- Vera Therapeutics recalls, complaints and regulation
History
Every quarter: Q3 2026 results